cancer

• 
• 
• 
• 

New research from a group of Vanderbilt biomedical engineers reveals that while cancer cells move quickly in metastasis, they’re rather lazy in which paths they choose.

Immune checkpoint inhibitors — cancer therapies that remove the “brakes” on the adaptive anti-tumor immune response — have had remarkable success in melanoma and lung cancer.

Cancer cells can develop resistance to the treatments designed to eliminate them. Several studies have linked stress granules (SGs), cell organelles that form transiently in response to extracellular stress, to this phenomenon. However, how SGs protect cancer cells remains unclear.